Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1

Aging Clinical Trial

— BrainFit  

Official title:

Physical Activity and Cognitive Function in Older Adults: A Novel Role for GPLD1

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04645134
• Other study ID #: PBRC 2020-050
• Status: Completed
• Start date: April 1, 2021
• Est. completion date: March 17, 2022

Study information

• Verified date: November 2022
• Source: Pennington Biomedical Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators are conducting a cross-sectional, observational study to investigate whether plasma GPLD1 concentrations are associated with higher cognitive function and better brain structure and function in two groups of older adults with high or low levels of physical activity.

Description:

This is a cross-sectional, observational study which will enroll up to 28 healthy, older adults (65-85 y, BMI 20-35 kg/m2), and stratify by current self-reported physical activity level (equal inactive vs. equal highly active).

Aim 1: Investigate whether physical activity level is associated with GPLD1.

Aim 2: Investigate whether cognitive function and brain structure/function are associated with GPLD1.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: March 17, 2022
• Est. primary completion date: March 17, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

Inclusion Criteria:

• Ages 65-85 y (inclusive)

• Body mass index (BMI) of 20-35 kg/m2 (inclusive)

• Willing to have blood and data stored for future research use

Exclusion Criteria:

• History of clinically diagnosed diabetes (Type 1 or 2) or a fasting blood glucose >126 mg/dL

• Diagnosed Alzheimer's disease, dementia, or related-brain diseases

• Chronic use of atypical antipsychotic or bipolar medications

• Initiation of novel pharmacotherapy agents (such as antidepressant, hypertension, or dyslipidemia) within the last 3 months

• Uncontrolled hypertension (blood pressure >160 systolic or >110 diastolic)

• Asthma that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration

• Emphysema that limits the ability to participate in moderate to vigorous physical activity or requiring systemic glucocorticoid administration

• Current alcohol use exceeding 14 drinks per week in women, exceeding 21 drinks per week in men, having treatment for alcohol abuse in the last year, or having treatment for alcohol abuse more than 1 year ago (but with inability to refrain from alcohol in the past year)

• Use of illegal drugs or marijuana within 1-month of completing a Screening Visit; treatment for drug addiction in the 1-year or having treatment for drug addiction >1-year ago, but with an inability to refrain from the drug of addiction in the 1-year

• Unwilling to abstain from illegal drugs and marijuana for the duration of the study

• Contraindication for MRI (e.g., metal objects, claustrophobia, etc.)

• Psychotic mental illness (e.g., schizophrenia, bipolar, on-and- off use of anti-psychotic medication)

• History of cardiovascular disease (or diseases of the heart, lungs, or blood) that limits participation in moderate to vigorous physical activity

• History of liver, blood, kidney, thyroid or other diseases that limits moderate to vigorous physical activity at the time of enrollment

• Cancer that limits moderate to vigorous physical activity

• Treatment with systemic immunosuppressant medication

• Taking adrenergic stimulants (e.g., amphetamine) or adrenergic blockers (e.g., Propanolol) that will alter metabolic rate

• Have plans to substantially alter their current level of physical activity over the next 1-month

Related Conditions & MeSH terms

• Aging
• Cognitive Dysfunction

Intervention

Behavioral:
• Brain Health Assessments
The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.

Locations

Country	Name	City	State
United States	Pennington Biomedical Research Center	Baton Rouge	Louisiana

Sponsors (1)

Lead Sponsor	Collaborator
Pennington Biomedical Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma concentrations of GPLD1	Plasma GPLD1 (by a blood draw) is performed.	1 day
Secondary	Physical activity level	Physical activity level assessment (by accelerometry) is performed.	7 days
Secondary	Total grey matter volume	Total grey matter volume (by structural MRI) is performed.	1 day
Secondary	Brain activity and function	Brain activity and function (by functional MRI) during execution of two cognitive tasks (Stroop Task and Attention Network Task (ANT)) is performed.	1 day
Secondary	Cognitive function	Cognitive function testing (using the NIH Toolbox Cognitive Battery) is performed.	1 day